• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

根据可切除性状态的胰腺癌多学科治疗方法

Multidisciplinary Therapeutic Approaches to Pancreatic Cancer According to the Resectability Status.

作者信息

Mauro Aurelio, Faverio Carlotta, Brizzi Leonardo, Mazza Stefano, Scalvini Davide, Alfieri Daniele, Cappellini Alessandro, Chicco Fabio, Ciccioli Carlo, Delogu Claudia, Bardone Marco, Gallotti Anna, Pagani Anna, Torello Viera Francesca, Anderloni Andrea

机构信息

Gastroenterology and Endoscopy Unit, IRCCS Foundation Policlinico San Matteo, 27100 Pavia, Italy.

Medical Oncology Unit, Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy.

出版信息

J Clin Med. 2025 Feb 11;14(4):1167. doi: 10.3390/jcm14041167.

DOI:10.3390/jcm14041167
PMID:40004698
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11856188/
Abstract

Pancreatic ductal adenocarcinoma (PDAC) is among the most lethal cancers, characterized by late diagnosis, rapid progression, and limited therapeutic options. Despite advancements, only 20% of patients are eligible for surgical resection at diagnosis, the sole curative treatment. Multidisciplinary evaluation is critical to optimize care, stratifying patients based on resectability into resectable, borderline resectable, locally advanced, and metastatic stages. Preoperative imaging, such as computed tomography (CT) and endoscopic ultrasound (EUS), remains central for staging, for vascular assessment, and tissue acquisition. Endoscopic and systemic approaches are pivotal for addressing complications like biliary obstruction and improving outcomes. Endoscopic retrograde cholangiopancreatography (ERCP) has been considered for years the gold standard for biliary drainage, although EUS-guided drainage is increasingly utilized due to its efficacy in both resectable and unresectable disease. Systemic therapies play a key role in neoadjuvant, adjuvant, and palliative settings, with ongoing trials exploring their impact on survival and resectability chance. This review highlights the evolving multidisciplinary approaches tailored to the disease stage, focusing on biliary drainage techniques, systemic therapies, and their integration into comprehensive care pathways for PDAC. The continuous refinement of these strategies offers incremental survival benefits and underscores the importance of personalized, multidisciplinary management.

摘要

胰腺导管腺癌(PDAC)是最致命的癌症之一,其特点是诊断较晚、进展迅速且治疗选择有限。尽管取得了进展,但只有20%的患者在诊断时符合手术切除条件,而手术切除是唯一的治愈性治疗方法。多学科评估对于优化治疗至关重要,它根据可切除性将患者分为可切除、边缘可切除、局部晚期和转移期。术前成像,如计算机断层扫描(CT)和内镜超声(EUS),对于分期、血管评估和组织获取仍然至关重要。内镜和全身治疗方法对于解决诸如胆道梗阻等并发症以及改善治疗效果至关重要。多年来,内镜逆行胰胆管造影(ERCP)一直被视为胆道引流的金标准,不过由于EUS引导下引流在可切除和不可切除疾病中均有效,其应用越来越广泛。全身治疗在新辅助、辅助和姑息治疗中发挥关键作用,目前正在进行试验以探索其对生存率和可切除机会的影响。本综述重点介绍了根据疾病阶段不断发展的多学科治疗方法,着重于胆道引流技术、全身治疗以及它们如何融入PDAC的综合治疗路径。这些策略的不断完善带来了逐步的生存益处,并强调了个性化多学科管理的重要性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7af5/11856188/c1a625ddc96c/jcm-14-01167-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7af5/11856188/e1078a542a6d/jcm-14-01167-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7af5/11856188/d11568af9f3c/jcm-14-01167-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7af5/11856188/9323e936c7c2/jcm-14-01167-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7af5/11856188/c1a625ddc96c/jcm-14-01167-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7af5/11856188/e1078a542a6d/jcm-14-01167-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7af5/11856188/d11568af9f3c/jcm-14-01167-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7af5/11856188/9323e936c7c2/jcm-14-01167-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7af5/11856188/c1a625ddc96c/jcm-14-01167-g004.jpg

相似文献

1
Multidisciplinary Therapeutic Approaches to Pancreatic Cancer According to the Resectability Status.根据可切除性状态的胰腺癌多学科治疗方法
J Clin Med. 2025 Feb 11;14(4):1167. doi: 10.3390/jcm14041167.
2
Pretherapeutic evaluation of patients with upper gastrointestinal tract cancer using endoscopic and laparoscopic ultrasonography.使用内镜超声和腹腔镜超声对上消化道癌患者进行治疗前评估。
Dan Med J. 2012 Dec;59(12):B4568.
3
Neoadjuvant and Adjuvant Treatments for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: The Current Status of Pancreatic Ductal Adenocarcinoma Treatment in Japan.可切除和交界可切除胰腺导管腺癌的新辅助和辅助治疗:日本胰腺导管腺癌治疗的现状。
Gut Liver. 2023 Sep 15;17(5):698-710. doi: 10.5009/gnl220311. Epub 2023 Feb 27.
4
New Frontiers in Pancreatic Cancer Management: Current Treatment Options and the Emerging Role of Neoadjuvant Therapy.胰腺癌管理的新前沿:当前治疗选择和新辅助治疗的新兴作用。
Medicina (Kaunas). 2024 Jun 28;60(7):1070. doi: 10.3390/medicina60071070.
5
High-resolution pancreatic computed tomography for assessing pancreatic ductal adenocarcinoma resectability: a multicenter prospective study.高分辨率胰腺 CT 评估胰腺导管腺癌可切除性:一项多中心前瞻性研究。
Eur Radiol. 2023 Sep;33(9):5965-5975. doi: 10.1007/s00330-023-09584-2. Epub 2023 Mar 29.
6
ELEMENT TRIAL: study protocol for a randomized controlled trial on endoscopic ultrasound-guided biliary drainage of first intent with a lumen-apposing metal stent vs. endoscopic retrograde cholangio-pancreatography in the management of malignant distal biliary obstruction.ELEMENT 试验:一项随机对照试验的研究方案,旨在比较内镜超声引导下胆管引流术(使用 lumen-apposing 金属支架)与内镜逆行胰胆管造影术(ERCP)在治疗恶性远端胆道梗阻中的疗效。
Trials. 2019 Dec 9;20(1):696. doi: 10.1186/s13063-019-3918-y.
7
Palliative management for malignant biliary obstruction and gastric outlet obstruction from pancreatic cancer.胰腺癌所致恶性胆道梗阻和胃出口梗阻的姑息治疗
Ann Gastroenterol Surg. 2024 Dec 26;9(2):218-225. doi: 10.1002/ags3.12902. eCollection 2025 Mar.
8
Endoscopic Evaluation in the Workup of Pancreatic Cancer.胰腺癌检查中的内镜评估
Surg Clin North Am. 2016 Dec;96(6):1257-1270. doi: 10.1016/j.suc.2016.07.006.
9
CT-determined resectability of borderline resectable and unresectable pancreatic adenocarcinoma following FOLFIRINOX therapy.CT 评估 FOLFIRINOX 治疗后边界可切除和不可切除胰腺腺癌的可切除性。
Eur Radiol. 2021 Feb;31(2):813-823. doi: 10.1007/s00330-020-07188-8. Epub 2020 Aug 26.
10
Endoscopic Ultrasound-Guided Biliary Drainage of First Intent With a Lumen-Apposing Metal Stent vs Endoscopic Retrograde Cholangiopancreatography in Malignant Distal Biliary Obstruction: A Multicenter Randomized Controlled Study (ELEMENT Trial).腔内贴壁金属支架与内镜逆行胰胆管造影术用于恶性远端胆管梗阻首次内镜超声引导下胆管引流的多中心随机对照研究(ELEMENT试验)
Gastroenterology. 2023 Nov;165(5):1249-1261.e5. doi: 10.1053/j.gastro.2023.07.024. Epub 2023 Aug 6.

本文引用的文献

1
Endoscopic ultrasound-guided choledochoduodenostomy versus hepaticogastrostomy combined with gastroenterostomy in malignant double obstruction (CABRIOLET_Pro): A prospective comparative study.内镜超声引导下胆总管十二指肠吻合术与肝胃吻合术联合胃肠吻合术治疗恶性双梗阻(CABRIOLET_Pro):一项前瞻性对比研究。
DEN Open. 2024 Oct 6;5(1):e70024. doi: 10.1002/deo2.70024. eCollection 2025 Apr.
2
Biliary drainage in patients with malignant distal biliary obstruction: results of an Italian consensus conference.恶性远端胆管梗阻患者的胆汁引流:意大利共识会议的结果。
Surg Endosc. 2024 Nov;38(11):6207-6226. doi: 10.1007/s00464-024-11245-4. Epub 2024 Sep 25.
3
Complications and management of interventional endoscopic ultrasound: A critical review.
介入性内镜超声的并发症及处理:批判性评价。
Best Pract Res Clin Gastroenterol. 2024 Mar;69:101888. doi: 10.1016/j.bpg.2024.101888. Epub 2024 Feb 2.
4
Outcomes predictors in endoscopic ultrasound-guided choledochoduodenostomy with lumen-apposing metal stent: Systematic review and meta-analysis.内镜超声引导下带管腔对接金属支架的胆总管十二指肠吻合术的预后预测因素:系统评价和荟萃分析
Endosc Int Open. 2024 Mar 28;12(3):E456-E462. doi: 10.1055/a-2271-2145. eCollection 2024 Mar.
5
Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trial.新辅助FOLFIRINOX方案与直接手术治疗可切除胰头癌的比较(NORPACT-1):一项多中心、随机、2期试验
Lancet Gastroenterol Hepatol. 2024 Mar;9(3):205-217. doi: 10.1016/S2468-1253(23)00405-3. Epub 2024 Jan 15.
6
Role of Endoscopic Ultrasound in Diagnosis of Pancreatic Ductal Adenocarcinoma.内镜超声在胰腺导管腺癌诊断中的作用
Diagnostics (Basel). 2023 Dec 28;14(1):78. doi: 10.3390/diagnostics14010078.
7
Folfirinox vs. Gemcitabine + Nab-Paclitaxel as the First-Line Treatment for Pancreatic Cancer: A Systematic Review and Meta-Analysis.Folfirinox方案与吉西他滨+纳米白蛋白紫杉醇作为胰腺癌一线治疗的系统评价和荟萃分析
World J Oncol. 2023 Oct;14(5):325-339. doi: 10.14740/wjon1604. Epub 2023 Sep 20.
8
Fully covered versus partially covered self-expandable metal stents for palliation of distal malignant biliary obstruction: a systematic review and meta-analysis.完全覆膜与部分覆膜自膨式金属支架治疗远端恶性胆道梗阻的疗效比较:系统评价和荟萃分析。
Gastrointest Endosc. 2024 Mar;99(3):314-322.e19. doi: 10.1016/j.gie.2023.10.023. Epub 2023 Oct 7.
9
NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial.NALIRIFOX 对比 nab-紫杉醇和吉西他滨用于治疗初治转移性胰腺导管腺癌(NAPOLI 3):一项随机、开放标签、3 期临床试验。
Lancet. 2023 Oct 7;402(10409):1272-1281. doi: 10.1016/S0140-6736(23)01366-1. Epub 2023 Sep 11.
10
Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.胰腺癌:欧洲肿瘤内科学会临床实践指南之诊断、治疗及随访
Ann Oncol. 2023 Nov;34(11):987-1002. doi: 10.1016/j.annonc.2023.08.009. Epub 2023 Sep 9.